Immunotherapy May Not Benefit All Gastroesophageal Cancer Patients, FDA Staff Says

An FDA advisory committee will consider whether PD-L1 expression cutoffs should guide use of checkpoint inhibitors to treat advanced gastroesophageal cancers.